Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))

M. Reck; T. E. Ciuleanu; M. Cobo; M. Schenker; B. Zurawski; J. Menezes; E. Richardet; J. Bennouna; E. Felip; O. Juan-Vidal; A. Alexandru; H. Sakai; A. Lingua; F. Reyes; P. J. Souquet; P. De Marchi; C. Martin; M. Pérol; A. Scherpereel; S. Lu; L. Paz-Ares; D. P. Carbone; A. Memaj; S. Marimuthu; X. Zhang; P. Tran; T. John

doi:10.1016/j.esmoop.2021.100345

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))

M. Reck, T. E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, F. Reyes, P. J. Souquet, P. De Marchi, C. Martin, M. Pérol, A. Scherpereel, S. LuL. Paz-Ares, D. P. Carbone, A. Memaj, S. Marimuthu, X. Zhang, P. Tran, T. John

Research output: Contribution to journal › Comment/debate

10 Scopus citations

Abstract

The authors regret that at the time the article was published there were some minor errors which have now been corrected. In Figure 4 (Grade 3/4 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected as per the below. In Supplementary Figure S12 (Grade 1/2 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected and a revised Supplementary Data file provided. The authors would like to apologize for any inconvenience caused.

Original language	English
Article number	100345
Journal	ESMO Open
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/j.esmoop.2021.100345
State	Published - Dec 2021

Access to Document

10.1016/j.esmoop.2021.100345

Fingerprint

Dive into the research topics of 'Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))'. Together they form a unique fingerprint.

Cite this

Reck, M., Ciuleanu, T. E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P. J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., ... John, T. (2021). Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273)). ESMO Open, 6(6), Article 100345. https://doi.org/10.1016/j.esmoop.2021.100345

Reck, M. ; Ciuleanu, T. E. ; Cobo, M. et al. / Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer : CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273)). In: ESMO Open. 2021 ; Vol. 6, No. 6.

@article{c55b212469364864b91b1f0ec70ff35e,

title = "Corrigendum to {\textquoteleft}First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update{\textquoteright}: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))",

abstract = "The authors regret that at the time the article was published there were some minor errors which have now been corrected. In Figure 4 (Grade 3/4 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected as per the below. In Supplementary Figure S12 (Grade 1/2 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected and a revised Supplementary Data file provided. The authors would like to apologize for any inconvenience caused.",

author = "M. Reck and Ciuleanu, {T. E.} and M. Cobo and M. Schenker and B. Zurawski and J. Menezes and E. Richardet and J. Bennouna and E. Felip and O. Juan-Vidal and A. Alexandru and H. Sakai and A. Lingua and F. Reyes and Souquet, {P. J.} and {De Marchi}, P. and C. Martin and M. P{\'e}rol and A. Scherpereel and S. Lu and L. Paz-Ares and Carbone, {D. P.} and A. Memaj and S. Marimuthu and X. Zhang and P. Tran and T. John",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = dec,

doi = "10.1016/j.esmoop.2021.100345",

language = "English",

volume = "6",

journal = "ESMO Open",

issn = "2059-7029",

number = "6",

}

Reck, M, Ciuleanu, TE, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, PJ, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P & John, T 2021, 'Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))', ESMO Open, vol. 6, no. 6, 100345. https://doi.org/10.1016/j.esmoop.2021.100345

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273)). / Reck, M.; Ciuleanu, T. E.; Cobo, M. et al.
In: ESMO Open, Vol. 6, No. 6, 100345, 12.2021.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer

T2 - CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))

AU - Reck, M.

AU - Ciuleanu, T. E.

AU - Cobo, M.

AU - Schenker, M.

AU - Zurawski, B.

AU - Menezes, J.

AU - Richardet, E.

AU - Bennouna, J.

AU - Felip, E.

AU - Juan-Vidal, O.

AU - Alexandru, A.

AU - Sakai, H.

AU - Lingua, A.

AU - Reyes, F.

AU - Souquet, P. J.

AU - De Marchi, P.

AU - Martin, C.

AU - Pérol, M.

AU - Scherpereel, A.

AU - Lu, S.

AU - Paz-Ares, L.

AU - Carbone, D. P.

AU - Memaj, A.

AU - Marimuthu, S.

AU - Zhang, X.

AU - Tran, P.

AU - John, T.

PY - 2021/12

Y1 - 2021/12

N2 - The authors regret that at the time the article was published there were some minor errors which have now been corrected. In Figure 4 (Grade 3/4 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected as per the below. In Supplementary Figure S12 (Grade 1/2 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected and a revised Supplementary Data file provided. The authors would like to apologize for any inconvenience caused.

AB - The authors regret that at the time the article was published there were some minor errors which have now been corrected. In Figure 4 (Grade 3/4 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected as per the below. In Supplementary Figure S12 (Grade 1/2 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected and a revised Supplementary Data file provided. The authors would like to apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85120448579&partnerID=8YFLogxK

U2 - 10.1016/j.esmoop.2021.100345

DO - 10.1016/j.esmoop.2021.100345

M3 - Comment/debate

C2 - 34864501

AN - SCOPUS:85120448579

SN - 2059-7029

VL - 6

JO - ESMO Open

JF - ESMO Open

IS - 6

M1 - 100345

ER -

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J et al. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273)). ESMO Open. 2021 Dec;6(6):100345. doi: 10.1016/j.esmoop.2021.100345

Abstract

Access to Document

Other files and links

Fingerprint

Cite this